Medicenna Announces the Finalization of the Terms of its Public Offering of Securities

Medicenna Therapeutics Corp. has announced the finalization of terms for its marketed underwritten public offering of securities, with units priced at $0.50 each. The offering, which is set to close on or around May 27, 2026, will consist of units that include one common share and one half of one warrant. Each whole warrant will allow the holder to acquire one common share at an exercise price of $0.65 for a period of three years following the closing date. The specific deal value has not been disclosed.

As a clinical-stage immunotherapy company, Medicenna focuses on developing innovative treatments targeting cancer and autoimmune diseases through its proprietary Superkine technology. The company’s lead programs, including MDNA11 and MDNA113, are designed to enhance the effectiveness of immune responses against tumors. MDNA11, a long-acting IL-2 Superkine, is engineered to preferentially stimulate cancer-fighting T cells and natural killer cells, while MDNA113 represents a novel approach combining PD-1 inhibition with IL-2 stimulation for solid tumors. These advancements position Medicenna at the forefront of biopharmaceutical innovation in oncology.

The proceeds from this offering are expected to be allocated primarily towards the clinical and regulatory development of Medicenna's lead programs, as well as for general corporate purposes. This strategic funding will enable the company to advance its clinical trials and regulatory submissions, which are critical for bringing its therapies to market. The involvement of Bloom Burton Securities Inc. as the sole agent for the offering underscores the importance of this capital raise in supporting Medicenna's growth trajectory.

The biotechnology sector has been characterized by a surge in investment activity, particularly in immunotherapy, as companies seek to develop novel treatments for cancer and other serious diseases. The successful completion of Medicenna's offering could signal investor confidence in the company's pipeline and the broader market's appetite for innovative biopharmaceutical solutions. As the industry continues to evolve, companies like Medicenna that leverage cutting-edge technologies may find themselves well-positioned to capitalize on emerging opportunities.

In conclusion, Medicenna Therapeutics Corp.'s public offering represents a significant step in its mission to advance groundbreaking therapies in the immunotherapy space. The anticipated closing of the offering and the strategic use of proceeds to fund clinical development will be closely monitored by investors and industry stakeholders alike. As the biotechnology sector remains dynamic, the outcomes of such offerings will play a crucial role in shaping the future landscape of cancer treatment and immunotherapy advancements.